Propofol Reduces Perioperative Remifentanil Requirements in a Synergistic Manner

Leiden University, Leyden, South Holland, Netherlands
Anesthesiology (Impact Factor: 6.17). 09/2003; 99(2):347-59. DOI: 10.1097/00000542-200308000-00016
Source: PubMed

ABSTRACT Remifentanil is often combined with propofol for induction and maintenance of total intravenous anesthesia. The authors studied the effect of propofol on remifentanil requirements for suppression of responses to clinically relevant stimuli and evaluated this in relation to previously published data on propofol and alfentanil.
With ethics committee approval and informed consent, 30 unpremedicated female patients with American Society of Anesthesiologists physical status class I or II, aged 18-65 yr, scheduled to undergo lower abdominal surgery, were randomly assigned to receive a target-controlled infusion of propofol with constant target concentrations of 2, 4, or 6 microg/ml. The target concentration of remifentanil was changed in response to signs of inadequate anesthesia. Arterial blood samples for the determination of remifentanil and propofol concentrations were collected after blood-effect site equilibration. The presence or absence of responses to various perioperative stimuli were related to the propofol and remifentanil concentrations by response surface modeling or logistic regression, followed by regression analysis. Both additive and nonadditive interaction models were explored.
With blood propofol concentrations increasing from 2 to 7.3 microg/ml, the C(50) of remifentanil decreased from 3.8 ng/ml to 0 ng/ml for laryngoscopy, from 4.4 ng/ml to 1.2 ng/ml for intubation, and from 6.3 ng/ml to 0.4 ng/ml for intraabdominal surgery. With blood remifentanil concentrations increasing from 0 to 7 ng/ml, the C(50) of propofol for the return to consciousness decreased from 3.5 microg/ml to 0.6 microg/ml.
Propofol reduces remifentanil requirements for suppression of responses to laryngoscopy, intubation, and intraabdominal surgical stimulation in a synergistic manner. In addition, remifentanil decreases propofol concentrations associated with the return of consciousness in a synergistic manner.

Download full-text


Available from: Jaap Vuyk, Jul 29, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: The optimal dose of propofol and remifentanil induction to minimize the cardiovascular response associ-ated with tracheal intubation may exist. We investigated the cardiovascular response associated with tracheal intubation when various continuous induction doses of remifentanil in combination with propofol were used. Methods: Seventy-five patients were randomly allocated into 1 of 3 groups: the R-0.4 P-1 group (remifentanil 0.4 μg/kg/min and propofol 1 mg/kg); the R-0.5 P-1 group (remifentanil 0.5 μg/kg/min and propofol 1 mg/kg); and the R-0.4 P-2 group (remifen-tanil 0.4 μg/kg/min and propofol 2 mg/kg). One minute after remifentanil infusion commenced, a bolus of propofol was injected. Rocuronium 1 mg/kg was administered 1 min after propofol injection following loss of consciousness. Con-trolled ventilation was then performed for 2 min, and the trachea was intubated 4 min after the start of the remifentanil infusion. The infusion rate of remifentanil was decreased to 0.1 μg/kg/min after intubation. Blood pressure (BP) and heart rate (HR) were measured during this period until 5 min after tracheal intubation. Results: The changes in BP re-sponse due to tracheal intubation in the R-0.4 P-1 group were greater than those in the other 2 groups, whereas the HR responses to tracheal intubation were similar among the 3 groups. Conclusion: The combination of remifentanil 0.4 μg/kg/min and propofol 1 mg/kg led to an exaggerated cardiovascular response to tracheal intubation compared with the other combination groups.
    Open Journal of Anesthesiology 01/2012; 02(04). DOI:10.4236/ojanes.2012.24035
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: To demonstrate the optimal dose of remifentanyl between 5, 7 and 10 ng/mL during laryngoscopy in ASA I and ASA II patients. To asses the hemodynamic response that occurs during laryngoscopy and intubation when using a remifentanyl dose of 5 to 10 ng/mL. To determine the optimal conditions for endotracheal intubation with the administration of a remifentanyl dose of 5 to 10 ng/mL by the Helbo Hansen's scale. Materials and methods: 51 patients being under general anesthesia for elective ASA I, and ASA II surgeries, rang-ing between 18 and 65 years old, randomly divided into 3 groups were included in this study; Remifentanyl dosages of 5 ng/mL, 7 ng/mL and 10 ng/mL; the following measurements were performed in preoperative, at surgery admis-sion, 1, 2 and 5 minutes from the intubation of the variables: blood pressure, heart rate, oxygen saturation and bispectral index. The patients were medicat-ed with midazolam, induced with remifentanyl at the established doses accord-ing to the group they belonged to (1, 1.4 and 2 µg/kg), cisatracurio (150 µg/kg) and propofol (2, 1.5 and 1 mg/kg) respectively. Results: There was a signifi-cant difference (p < 0.05) in heart rate and blood pressure during the first minute at the laryngoscopy and in the group of remifentanyl at doses of 7 and 10 ng/mL. In addition to this, the conditions for the intubation, measured through the Helbo-Hansen's scale, from the remifentanyl Group at 10 ng/mL were more favorable than in the other groups. Conclusion: The study concludes that a remifentanyl dose of 10 ng/mL in the therapeutic window, combined with propo-fol at a dose of 1 mg/kg, provides excellent intubation conditions and increased hemodynamic stability during laryngoscopy and endotracheal intubation.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The anilidopiperidine opioid remifentanil has pharmacodynamic properties similar to all opioids; however, its pharmacokinetic characteristics are unique. Favourable pharmacokinetic properties, minimally altered by extremes of age or renal or hepatic dysfunction, enable easy titration and rapid dissipation of clinical effect of this agent, even after prolonged infusion. Remifentanil is metabolised by esterases that are widespread throughout the plasma, red blood cells, and interstitial tissues, whereas other anilidopiperidine opioids (e.g. fentanyl, alfentanil and sufentanil) depend upon hepatic biotransformation and renal excretion for elimination. Consequently, remifentanil is cleared considerably more rapidly than other anilidopiperidine opioids. In addition, its pKa (the pH at which the drug is 50% ionised) is less than physiological pH; thus, remifentanil circulates primarily in the non-ionised moiety, which quickly penetrates the lipid blood-brain barrier and rapidly equilibrates across the plasma/effect site interface. By virtue of these distinctive pharmacokinetic properties, the context-sensitive half-time (i.e. the time required for the drug's plasma concentration to decrease by 50% after cessation of an infusion) of remifentanil remains consistently short (3.2 minutes), even following an infusion of long duration (> or =8 hours). Remifentanil, a clinically versatile opioid, is useful for intravenous analgesia and sedation in spontaneously breathing patients undergoing painful procedures. Profound analgesia may be achieved with minimal effect on cognitive function. Remifentanil may also provide sedation and analgesia during placement of regional anaesthetic blocks, and in conjunction with topical anaesthesia and airway nerve blocks, it may be useful for blunting reflex responses and facilitating 'awake' fibreoptic intubation. Compared with fentanyl and alfentanil in a day-surgery setting, remifentanil supplementation of general anaesthesia may improve intraoperative haemodynamic control. Both emergence time and the incidence of respiratory depression during post-anaesthetic recovery may be reduced. However, outcomes such as home discharge time, post-emergence adverse effect profile, and patient and provider satisfaction are not significantly improved, and the incidence of intraoperative hypotension and bradycardia is greater. In addition, drug acquisition costs for remifentanil are higher and clinicians may need extra time to familiarise themselves with the drug's unique pharmacokinetics.Ironically, the quick dissipation of opioid analgesic effect following remifentanil discontinuation may be a significant clinical disadvantage. Unless little or no postoperative pain is anticipated, the clinician may wish to treat prospectively using local or regional anaesthesia, non-opioid analgesics, or longer-acting opioid analgesics.
    CNS Drugs 02/2004; 18(15):1085-104. · 4.38 Impact Factor
Show more